Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases

IF 3.7 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Annals of hepatology Pub Date : 2025-01-01 DOI:10.1016/j.aohep.2024.101750

Yiyuan Xiao , Sihua Xu , Wenyan Hu , Jiapeng Huang , Deke Jiang , Rong Na , Zhaoqing Yin , Jingjing Zhang , Haitao Chen

{"title":"Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases","authors":"Yiyuan Xiao , Sihua Xu , Wenyan Hu , Jiapeng Huang , Deke Jiang , Rong Na , Zhaoqing Yin , Jingjing Zhang , Haitao Chen","doi":"10.1016/j.aohep.2024.101750","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>Recently, Delphi consensus proposed an overarching term steatotic liver disease (SLD), with various subcategories such as MASLD, MetALD and ALD. Our aim was to investigate the association between MASLD/MetALD/ALD and four intrahepatic and extrahepatic diseases (liver diseases, renal diseases, cardiovascular diseases, and cancers) in the UK Biobank cohort.</div></div><div><h3>Patients and Methods</h3><div>By defining hepatic steatosis as image-derived phenotype (IDP)-PDFF >5.21%, we used data from the UK Biobank to diagnose MASLD/ MetALD/ALD. The odd ratio (OR) and the hazard ratio (HR) were calculated using the logistic regression modals and Cox regression models, respectively.</div></div><div><h3>Results</h3><div>Among 39,230 eligible individuals, 6,865 MASLD subjects, 2,379 MetALD subjects and 884 ALD subjects were diagnosed. The last follow-up time was October 13, 2023. Consistent with the logistic analyses, MASLD/MetALD/ALD were significantly associated with a higher risk of liver diseases (HR=3.04 [95%CI:2.60-3.56], HR = 2.69 [95% CI: 2.12-3.42] and HR =3.99 [95%CI:2.92-5.45], respectively). Subjects with MASLD also had an increased higher risk of renal diseases (HR = 1.40 [95%CI:1.20-1.64]) and subjects with ALD had an increased higher risk of cancers (HR = 1.36 [95%CI:1.15-1.60]).</div></div><div><h3>Conclusion</h3><div>It is the first study to report the association between MASLD, MetALD, ALD and common intrahepatic and extrahepatic diseases based on magnetic resonance imaging data—PDFF. We found that MASLD, MetALD and ALD were risk factors for liver diseases. Meanwhile, MASLD was also a risk factor for renal diseases and ALD was a risk factor for cancers.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 1","pages":"Article 101750"},"PeriodicalIF":3.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of hepatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1665268124005337","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction and Objectives

Recently, Delphi consensus proposed an overarching term steatotic liver disease (SLD), with various subcategories such as MASLD, MetALD and ALD. Our aim was to investigate the association between MASLD/MetALD/ALD and four intrahepatic and extrahepatic diseases (liver diseases, renal diseases, cardiovascular diseases, and cancers) in the UK Biobank cohort.

Patients and Methods

By defining hepatic steatosis as image-derived phenotype (IDP)-PDFF >5.21%, we used data from the UK Biobank to diagnose MASLD/ MetALD/ALD. The odd ratio (OR) and the hazard ratio (HR) were calculated using the logistic regression modals and Cox regression models, respectively.

Results

Among 39,230 eligible individuals, 6,865 MASLD subjects, 2,379 MetALD subjects and 884 ALD subjects were diagnosed. The last follow-up time was October 13, 2023. Consistent with the logistic analyses, MASLD/MetALD/ALD were significantly associated with a higher risk of liver diseases (HR=3.04 [95%CI:2.60-3.56], HR = 2.69 [95% CI: 2.12-3.42] and HR =3.99 [95%CI:2.92-5.45], respectively). Subjects with MASLD also had an increased higher risk of renal diseases (HR = 1.40 [95%CI:1.20-1.64]) and subjects with ALD had an increased higher risk of cancers (HR = 1.36 [95%CI:1.15-1.60]).

Conclusion

It is the first study to report the association between MASLD, MetALD, ALD and common intrahepatic and extrahepatic diseases based on magnetic resonance imaging data—PDFF. We found that MASLD, MetALD and ALD were risk factors for liver diseases. Meanwhile, MASLD was also a risk factor for renal diseases and ALD was a risk factor for cancers.

查看原文本刊更多论文

代谢功能障碍相关的脂肪变性肝病和四种肝内和肝外疾病的风险：MASLD和四种相关疾病的风险

简介和目标：最近，德尔菲共识提出了一个总体术语脂肪变性肝病（SLD），包括各种亚类别，如MASLD， MetALD和ALD。我们的目的是在英国生物银行队列中调查MASLD/MetALD/ALD与四种肝内和肝外疾病（肝脏疾病、肾脏疾病、心血管疾病和癌症）之间的关系。患者和方法：通过将肝脂肪变性定义为图像衍生表型(IDP)-PDFF >5.21%，我们使用英国生物银行的数据来诊断MASLD/ MetALD/ALD。分别采用logistic回归模型和Cox回归模型计算奇数比（OR）和风险比（HR）。结果：在39,230名符合条件的受试者中，有6,865名MASLD受试者，2,379名MetALD受试者和884名ALD受试者被诊断。最后一次随访时间是2023年10月13日。与logistic分析一致，MASLD/MetALD/ALD与肝脏疾病的高风险显著相关（HR=3.04 [95%CI:2.60 ~ 3.56], HR = 2.69 [95%CI: 2.12 ~ 3.42]和HR= 3.99 [95%CI:2.92 ~ 5.45]）。MASLD患者患肾脏疾病的风险也增加（HR = 1.40 [95%CI:1.20 ~ 1.64]）， ALD患者患癌症的风险增加（HR = 1.36 [95%CI:1.15 ~ 1.60]）。结论：该研究首次报道了基于磁共振成像数据pdff的MASLD、MetALD、ALD与常见肝内和肝外疾病的相关性。我们发现MASLD、MetALD和ALD是肝脏疾病的危险因素。同时，MASLD也是肾脏疾病的危险因素，ALD是癌症的危险因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of hepatology 医学-胃肠肝病学

CiteScore

7.90

自引率

2.60%

发文量

183

审稿时长

4-8 weeks

期刊介绍： Annals of Hepatology publishes original research on the biology and diseases of the liver in both humans and experimental models. Contributions may be submitted as regular articles. The journal also publishes concise reviews of both basic and clinical topics.